- Home
- ATNM vs MDAI Comparison
ATNM vs MDAI Comparison
Compare ATNM & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- MDAI
- Stock Information
- Founded
- ATNM 2000
- MDAI 2013
- Country
- ATNM United States
- MDAI United States
- Employees
- ATNM N/A
- MDAI N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- ATNM Health Care
- MDAI Health Care
- Exchange
- ATNM Nasdaq
- MDAI Nasdaq
- Market Cap
- ATNM 51.5M
- MDAI 51.5M
- IPO Year
- ATNM N/A
- MDAI N/A
- Fundamental
- Price
- ATNM $1.52
- MDAI $2.12
- Analyst Decision
- ATNM Strong Buy
- MDAI Strong Buy
- Analyst Count
- ATNM 3
- MDAI 2
- Target Price
- ATNM $4.67
- MDAI $4.75
- AVG Volume (30 Days)
- ATNM 246.6K
- MDAI 455.5K
- Earning Date
- ATNM 08-04-2025
- MDAI 08-11-2025
- Dividend Yield
- ATNM N/A
- MDAI N/A
- EPS Growth
- ATNM N/A
- MDAI N/A
- EPS
- ATNM N/A
- MDAI N/A
- Revenue
- ATNM N/A
- MDAI $29,962,000.00
- Revenue This Year
- ATNM N/A
- MDAI N/A
- Revenue Next Year
- ATNM N/A
- MDAI $56.05
- P/E Ratio
- ATNM N/A
- MDAI N/A
- Revenue Growth
- ATNM N/A
- MDAI 55.21
- 52 Week Low
- ATNM $1.03
- MDAI $0.82
- 52 Week High
- ATNM $8.64
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- ATNM 42.39
- MDAI 67.16
- Support Level
- ATNM $1.41
- MDAI $1.97
- Resistance Level
- ATNM $1.95
- MDAI $2.28
- Average True Range (ATR)
- ATNM 0.13
- MDAI 0.16
- MACD
- ATNM -0.04
- MDAI 0.01
- Stochastic Oscillator
- ATNM 6.54
- MDAI 82.81
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.